covid
Buscar en
Endocrinología y Nutrición (English Edition)
Toda la web
Inicio Endocrinología y Nutrición (English Edition) Differentiated thyroid carcinoma: survival and prognostic factors
Journal Information
Vol. 58. Issue 4.
Pages 157-162 (April 2011)
Share
Share
Download PDF
More article options
Vol. 58. Issue 4.
Pages 157-162 (April 2011)
Special article
Full text access
Differentiated thyroid carcinoma: survival and prognostic factors
Carcinoma diferenciado de tiroides: supervivencia y factores relacionados
Visits
1732
Julia Sastre Marcosa,
Corresponding author
jsastrem@sescam.jccm.es

Corresponding author.
, Ofelia Llamazares Iglesiasa, Almudena Vicente Delgadoa, Amparo Marco Martíneza, Bárbara Cánovas Gaillemina, Juan Luis Orradre Romerob, Miguel Ángel Morlan Lópezc, José López Lópeza
a Sección de Endocrinología y Nutrición, Hospital Virgen de la Salud, Complejo Hospitalario de Toledo, Toledo, Spain
b Servicio de Anatomía Patológica, Hospital Virgen de la Salud, Complejo Hospitalario de Toledo, Toledo, Spain
c Servicio de Cirugía General, Hospital Virgen de la Salud, Complejo Hospitalario de Toledo, Toledo, Spain
This item has received
Article information
Abstract
Bibliography
Download PDF
Statistics
Abstract
Background and aims

Differentiated thyroid carcinoma (DTC) is the most common endocrine tumor. DTC has a good prognosis and survival rates are higher than 85%. The aim of our study was to assess our current survival rate and to analyze prognostic factors.

Patients and methods

A retrospective study was conducted of 308 patients with DTC (93.5% with papillary tumors, 78.8% females). Mean age at diagnosis was 45.4±15.8 years, and mean follow-up time was 8.9±6.8 years. The whole group was treated and followed up using the same protocol at our hospital. The following data were collected: age at diagnosis, sex, histology, TNM stage, treatments, and date and cause of death. Survival probability was calculated using Kaplan-Meier analyses. Prognostic factors were analyzed using a univariate log rank test and a multivariate Cox regression analysis model.

Results

Twenty-six patients died during follow-up, 15 of them (4.9%) from DTC. Thyroid carcinoma-related survival was 92.7% for the whole group. Variables independently associated with a significantly increased risk of death from DTC in multivariate analyses included distant metastases, follicular histology, age at diagnosis older than 60 years, and extrathyroid involvement.

Discussion

The survival rate in our series was similar to that reported in the literature. However, assessment of the prognostic factors related to an increased risk of death within our patient group is necessary in order to establish active therapeutic approaches for high risk patients.

Keywords:
Differentiated thyroid carcinoma
Survival
Risk factors
Resumen
Antecedentes y objetivo

El cáncer diferenciado de tiroides (CDT) es el tumor endocrino más frecuente, con buen pronóstico y supervivencias superiores al 85%. El objetivo de nuestro trabajo es conocer la supervivencia actual de nuestra serie de CDT y analizar los factores relacionados.

Pacientes y métodos

Realizamos un estudio retrospectivo de una cohorte de pacientes con CDT (n: 308), 93,5% eran papilares, el 78,2% eran mujeres con una edad media al diagnóstico de 45,4±15,8 años y un tiempo de seguimiento de 8,9±6,8 años. Han sido tratados y seguidos de forma homogénea en nuestro centro hospitalario. Para cada paciente se ha recogido edad al diagnóstico, sexo, histología, estadio TNM, tratamientos empleados y fecha y causa de la muerte. La probabilidad de supervivencia fue calculada por el método de Kaplan Meier. Para analizar los factores relacionados con la supervivencia se realizó un análisis univariante (Log Rank test) y multivariante (Riesgos proporcionales de Cox).

Resultados

Se produjeron 26 casos de muerte, de ellos 15 pacientes (4,9%) murieron como consecuencia del CDT. La probabilidad de supervivencia acumulada del grupo total fue del 92,7%. En el análisis multivariante las variables asociadas de forma independiente con mortalidad por CDT fueron: metástasis a distancia, tipo histológico folicular, edad al diagnóstico más de 60 años y afectación extratiroidea.

Discusión

La probabilidad de supervivencia de nuestra serie es equiparable a la de la literatura. El conocimiento de los factores relacionados con peor supervivencia en el medio que trabajamos es importante para establecer estrategias más activas de tratamiento en pacientes de alto riesgo.

Palabras clave:
Carcinoma diferenciado de tiroides
Supervivencia
Factores de riesgo
Full text is only aviable in PDF
References
[1.]
L. Davies, H.G. Welch.
Increasing incidence of thyroid cancer in the United States, 1973–2002.
JAMA, 295 (2006), pp. 2164-2167
[2.]
A. Riego-Iraeta, L.F. Pérez-Méndez, B. Mantinan, R.V. García-Mayor.
Time trends for thyroid cancer in northwestern Spain: True rise in the incidence of micro and larger forms of papillary thyroid carcinoma.
Thyroid, 19 (2009), pp. 333-340
[3.]
J. Albores-Saavedra, D.E. Henson, E. Glazer, A.M. Schwartz.
Changing patterns in the incidence and survival of thyroid cancer with follicular phenotype: papillary, follicular and anaplastic: a morphological and epidemiological study.
Endocr Pathol, 18 (2007), pp. 1-7
[4.]
C.F.A. Eustatia-Rutten, E.P.M. Corssmit, N.R. Biermasz, A.M. Pereira, J.A. Romijn, J.W. Smit.
Survival and death causes in differentiated thyroid carcinoma.
J Clin Endocrinol Metab, 91 (2006), pp. 313-319
[5.]
A. Toniato, I. Boschin, D. Casara, R. Mazzarotto, D. Rubello, M. Pelizzo.
Papillary thyroid carcinoma: factors influencing recurrence and survival.
Ann Surg Oncol, 15 (2008), pp. 1518-1522
[6.]
Y. Ito, A. Miyauchi.
Prognostic factors and therapeutic strategies for differentiated carcinomas of the thyroid.
Endocrine J, 56 (2009), pp. 177-192
[7.]
M. Pelizzo, I.M. Boschin, A. Toniato, A. Piotto, C. Pagetta, M.D. Gross, et al.
Papillary thyroid carcinoma: 35 year outcome and prognostic factors in 1858 patients.
Clin Nucl Med, 32 (2007), pp. 440-444
[8.]
B.H. Lang, C.Y. Lo, W.F. Chan, K.Y. Lam, K.Y. Wan.
Staging systems for papillary thyroid carcinoma. A review and comparison.
[9.]
E. Rosei, C. Ugolini, D. Viola, C. Lupi, A. Biagini, R. Gianini, et al.
BRAF v600e mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study.
J Clin Endocrinol Metab, 93 (2008), pp. 3943-3949
[10.]
Histological typing of thyroid tumours.
International histological classification of tumours, no, pp. 1-18
[11.]
L.H. Sobin, C. Wittekind.
UICC: TNM Classification of malignant Tumors.
6th ed, Wiley-Liss, (2002),
[12.]
J. Sastre, A. Vicente, J. López, M.A. Carrasco, M. Mollejo, J.L. Orradre.
Morbidity and mortality in differentiated thyroid carcinoma: our experience.
IV European Congress of Endocrinology,
[13.]
J. Sastre, A. Vicente, A. Marco, B. Cánovas, J. López, M. Mollejo, et al.
Factores pronósticos de supervivencia- recidiva en el carcinoma diferenciado de tiroides en el área de Toledo. 45 Congreso Nacional de la Sociedad Española de Endocrinología y Nutrición. Cáceres, Mayo 2003.
Endocrinol Nutr, 50 (2003), pp. 45
[14.]
C. Zafón, J. Castelvi, G. Obiols.
Utilidad del análisis inmunohistoquímico de diversos marcadores moleculares en la caracterización del carcinoma papilar de tiroides con metástasis linfáticas iniciales.
Endocrinol Nutr, 57 (2010), pp. 165-169
[15.]
D.S. Cooper, G.D. Doherty, B.R. Haugen, R.T. Kloos, S.L. Lee, S.L. Mandel, et al.
Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer.
Thyroid, 19 (2009), pp. 1167-1214
[16.]
J.M. Gómez.
Toma de posición en relación con el protocolo de tratamiento actual del nódulo y cáncer diferenciado de tiroides.
Endocrinol Nutr, 57 (2010), pp. 370-375
[17.]
J.C. Galofré.
Manejo del cáncer de tiroides en España.
Endocrinol Nutr, 57 (2010), pp. 347-349
[18.]
J.P. Shah, T.R. Loree, D. Dharker, E.W. Strong, C. Begg, V. Vlamis.
Prognostic factors in differentiated carcinoma of the thyroid gland.
Am J Surg, 164 (1992), pp. 658-661
[19.]
C.I. Lundgren, P. Hall, A. Ekbom, J. Frisell, J. Zedenius, P.W. Dickman.
Incidence and survival of Swedish patients with differentiated thyroid cancer.
Int J Cancer, 106 (2003), pp. 569-573
[20.]
L.A. Akslen, T. Haldorsen, S.O. Thoresen, E. Glattre.
Survival and causes of death in thyroid cancer: a population-based study of 2479 cases from Norway.
Cancer Res, 51 (1991), pp. 1234-1241
[21.]
W. Eichhorn, H. Tabler, R. Lippold, M. Lochman, M. Schreckenberger, P. Bartenstein.
Prognostic factors determining long-term survival in well-differentiated thyroid cancer: an analysis of four hundred eighty-four patients undergoing therapy and aftercare at the same institution.
Thyroid, 13 (2003), pp. 949-958
[22.]
M. Schlumberger, S.I. Sherman.
Clinical trials for progressive differentiated thyroid cancer: patient selection, study design and recent advances.
Thyroid, 12 (2009), pp. 1393-1400
[23.]
Lope V, Pollán M, Pérez-Gómez B, Aragonés N, Ramis R, Gómez-Barroso D, et al. Municipal mortality due to thyroid cancer in Spain. BMC Public Health 6: 302-. Doi: 1186/1471-2458r-r6-302.
[24.]
I.D. Hay, G.B. Thompson, C.S. Grant, E.J. Bergstralh, C.E. Dvorak, C.A. Gorman, et al.
Papillary thyroid carcinoma managed at the Mayo Clinic Turing six decades (1940–1999) temporal trends in initial therapy and long- term outcome in 2,444 consecutively treated patients.
World J Surg, 26 (2002), pp. 879-885
[25.]
V. Alcázar, B.M. Mondéjar, T.L. del Val, P.M. de Icaya, D. del Olmo, M.A. Jaunsolo, et al.
Tasa de incidencia y características del cáncer de tiroides en un área de la zona sur de Madrid.
Endocrinol Nutr, 47 (2000), pp. 182-184
[26.]
C. Familiar, I. Moraga, T. Antón, M.A. Gargallo, A. Ramos, A.L. Marco, et al.
Factores relacionados con la persistencia de la enfermedad a los 5 años del diagnóstico de cáncer diferenciado de tiroides: estudio de 63 pacientes.
Endocrinol Nutr, 56 (2009), pp. 361-368
[27.]
J.L. Reverter, E. Colomé, I. Halperin, T. Julian, G. Díaz, A. Sanmartí, et al.
Estudio comparativo de las series históricas de carcinoma diferenciado de tiroides en dos centros hospitalarios de tercer nivel.
Endocrinol Nutr, 57 (2010), pp. 364-369
Copyright © 2011. Sociedad Española de Endocrinología y Nutrición
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos